Given the absence of Bcl-XL dependence, we hypothesized that select Bcl-2 antagonism would be equally as potent as ABT-737 in killing NB tumors and eventually result in less hematologic side effects when translated in the clinic. This evidence concerns the gene BCL2L1 and neuroblastoma.